C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Breast Neoplasms
Disease Progression
Disease-Free Survival
Female
Fibrocystic Breast Disease
Hepatocyte Growth Factor
Humans
Hyperplasia
Ligands
Lymph Nodes
Lymphatic Metastasis
Middle Aged
Neoplasm Staging
Pilot Projects
Proto-Oncogene Proteins c-met
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Risk Factors
Survival Rate
Treatment Outcome

authors with profiles

Ernst Robert Lengyel